methylphenidate has been researched along with Nerve Degeneration in 4 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate is a piperidine derivative and is the drug most often used to treat attention deficit/hyperactivity disorder of children and young adults." | 1.35 | Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat. ( Bahcelioglu, M; Bardakci, Y; Calguner, E; Elmas, C; Erdogan, D; Gozil, R; Kadioglu, D; Oktem, H; Sargon, MF; Senol, S; Take, G; Tas, M; Yazici, AC, 2009) |
| "The causes of nigrostriatal neuron degeneration in Parkinson's disease (PD) are not known, but it has been suggested that exogenous or endogenous factors or neurotoxins may play a role." | 1.33 | An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. ( Delville, Y; Fleming, SM; Schallert, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Motaghinejad, M | 1 |
| Motevalian, M | 1 |
| Abdollahi, M | 1 |
| Heidari, M | 1 |
| Madjd, Z | 1 |
| Bahcelioglu, M | 1 |
| Gozil, R | 1 |
| Take, G | 1 |
| Elmas, C | 1 |
| Oktem, H | 1 |
| Kadioglu, D | 1 |
| Calguner, E | 1 |
| Erdogan, D | 1 |
| Sargon, MF | 1 |
| Yazici, AC | 1 |
| Tas, M | 1 |
| Bardakci, Y | 1 |
| Senol, S | 1 |
| Lange, M | 1 |
| Norton, W | 1 |
| Coolen, M | 1 |
| Chaminade, M | 1 |
| Merker, S | 1 |
| Proft, F | 1 |
| Schmitt, A | 1 |
| Vernier, P | 1 |
| Lesch, KP | 1 |
| Bally-Cuif, L | 1 |
| Fleming, SM | 1 |
| Delville, Y | 1 |
| Schallert, T | 1 |
4 other studies available for methylphenidate and Nerve Degeneration
| Article | Year |
|---|---|
Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal; Cyclic AMP Response | 2017 |
Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat.
Topics: Administration, Oral; Age Factors; Animals; Astrocytes; Capillaries; Central Nervous System Stimulan | 2009 |
The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diencephalon; Dis | 2012 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Dise | 2005 |